Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer

CONCLUSIONS: Despite the higher cost, adding dostarlimab to platinum chemotherapy significantly improves QALYs, rendering this regimen cost-effective relative to chemotherapy alone for treating primary advanced or recurrent EC. Combination therapy is a cost-effective approach for this patient population compared to chemotherapy alone.PMID:38554477 | DOI:10.1016/j.ygyno.2024.03.020

Source: Gynecologic Oncology - March 30, 2024 Category: Cancer & Oncology Authors: Courtney J Riedinger David A Barrington Christa I Nagel Wafa K Khadraoui Paulina J Haight Crystal Tubbs Floor J Backes David E Cohn David M O'Malley Larry J Copeland Laura M Chambers Source Type: research